Gilead slashes cardio salesforce to cope with Letairis, Ranexa generics

Gilead
Gilead Sciences is laying off 150 in its sales force to deal with patent expirations. (Gilead China)

Staring down the barrel of two key patent expirations, Gilead Sciences is sharpening its job-cutting ax. The California drugmaker will cut loose 150 salespeople who rep its cardiopulmonary drugs, a $1.7 billion franchise set for generic competition this year.

The layoffs are part of a cost-cutting plan the company rolled out in 2017 as it braced for Letairis and Ranexa generics, Gilead spokesperson Marni Kottle told FiercePharma via email. 

"Gilead has worked with the impacted employees to provide ample notice and to help them plan for their transitions," Kottle said. "The efforts and dedication of our cardiopulmonary employees have been deeply appreciated."

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Pulmonary arterial hypertension med Letairis, which pulled in $943 million in the U.S. last year, is expected to lose exclusivity by the end of this quarter, Gilead CFO Robin Washington said during an earnings conference call. Chest pain med Ranexa pulled in $756 million in the U.S. last year, and it's already facing off against exclusive generics from Lupin. Together, Gilead expects those generics to take a $1.1 billion to $1.2 billion bite out of sales this year.

RBC Capital Markets analyst Brian Abrahams said the layoffs weren't a surprise. The job cuts are a “culmination of a long-term strategy and events, and [are] not representative of any specific new or different plan being implemented by the company's CEO," Abrahams wrote in a note to investors.

Nevertheless, the layoffs are among the first public moves authorized by Gilead's brand-new CEO, Dan O’Day, who joined the company last month from Roche. Gilead has been struggling with hepatitis C competition for years, and market watchers saw O’Day’s appointment as a signal that Gilead would look to oncology for growth. 

At least in the short term, the company’s new cancer cell therapy Yescarta isn’t chipping in enough sales to offset Gilead's flagging hep C business. Last year, the CAR-T drug generated $264 million. Gilead's hep C drugs have churned out billions in sales, but the company's revenues in the field have cratered on increasing competition and pricing pressures.

Suggested Articles

Alcon has many "mass and structural advantages" over "distant" follower Bausch, which spends a lot less on R&D, says one analyst.

The judge in a multistate case against opioid makers scoffed at their request for more time to review an estimate that they owe $480 billion in damages.

Indian drugmakers pick up U.S. generics scripts; Chi-Med files for Hong Kong listing; an explosion at a Qilu Pharma subsidiary kills 10.